PDGFR inhibition accelerates disease progression in men with mCRPC

A while back now the research group at M. D. Anderson Cancer Center initiated a Phase II clinical trial of a drug called tandutinib in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who had already had taxane-based chemotherapy. … READ MORE …

Your Friday news update: November 28, 2008

In today’s news reports, among other items, we cover:

  • Risk for prostate cancer 4 years after initial screening
  • Presumptive antibiotic therapy for an elevated PSA level
  • The morphology of cancer cell nuclei in men with Gleason 7 disease
  • MRI in prostate cancer diagnosis and staging
  • PDGFR levels and the efficacy of docetaxel (Taxotere) … READ MORE …